Advertisement

Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Varsha Gandhi, PhD, on Ibrutinib

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Advertisement

Advertisement




May
08
Today In Oncology
Bavituximab Plus Pembrolizumab for Patients With Hepatocellular Carcinoma
Effects of Radiation Therapy Timing on Lifespan of Artificial Urinary Sphincters in Prostate Cancer Survivors
Hemihepatectomy Outcomes With Laparoscopic vs Open Surgery
T-DXd vs Physicians Choice of Therapy in HER2-Positive Metastatic Breast Cancer PROs in DESTINY-Breast02
Novel Urine Biomarker Test May Reduce Unnecessary Cystoscopies in Patients With Bladder Cancer
View More 
Advertisement
© 2024 HSP News Service, L.L.C.
Designed by Harborside